Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Antithrombin Market to Exhibit 4.1% CAGR, Rising Prevalence of Hereditary Antithrombin Deficiency to Boost Market Forecast Till 2026

Antithrombin Market to Reach US$ 725.2 Mn, Therapeutics Segment to Lead Market Forecast till 2026

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 06/14/2019 -- Rising demand for Therapeutics segment is prognosticated to emerge dominant among various applications in the global Antithrombin Market, finds Fortune Business Insights in a new study. The study is titled "Antithrombin Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2026." According to the study, the global antithrombin market will exhibit a steady CAGR of 4.1% to reach a value of US$ 725.2 Mn by 2026 from US$ 490.4 Mn in 2018.

Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antithrombin-market-100470

According to the U.S. Department of Health and Human services in 2018, antithrombin deficiency is likely to occur about 1 in every 2000 person globally. The fact that antithrombin combines with heparin and can be used for treating congenital antithrombin III deficiency is expected to boost the market in the long run.

Increasing Prevalence of Hereditary Antithrombin Deficiency to Boost Market

The rising prevalence of medical conditions such as sepsis, hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and extracorporeal membrane oxygenation (ECMO) is creating lucrative growth opportunities for the antithrombin market. Among various application types, the therapeutics segment is anticipated to lead the market with a rising number of antithrombin deficiency cases. In 2018, the therapeutics segment accounted for about 95.7% market share and is likely to continue its dominance in the future as Fortune Business Insights analysts say.

However, the high treatment cost of antithrombin may cause end users to opt for cheaper alternatives or supplements. This may hamper the market globally. Again, the developing countries of Asia Pacific may directly opt out of adopting antithrombin treatment because of the high price of this treatment. This may pose a challenge for market players to generate revenue from this region, thus, hampering the overall profit percentage of the market.

The Asia Pacific to Emerge as the Fastest Growing Region, with Rising Disposable Incomes

Geographically, the Global Antithrombin Market is anticipated to be showing the fastest growth in the Asia Pacific. In 2018, the antithrombin market earned about US$ 179.7 Mn from the Asia Pacific alone. A major reason behind this growth is the fact that developing nations such as India and China are adopting new treatment procedures and techniques to fight back various diseases. The rise in disposable incomes of people in developing nations and their increasing ability to spend more on healthcare and medical aid will create lucrative growth opportunities for the market in the Asia Pacific.

Again, Europe is expected to have huge potential for growth for antithrombin market during the forecast period. This is because countries such as the UK, Germany, France, and others are considerably adopting human antithrombin based products on a large scale.

The global antithrombin market is expected to be dominated by three major companies namely SCL Behring, Grifols, and the Shire. In 2018, these three companies together accounted for the highest market share among others. They offer the most commonly used human antithrombin based anticoagulants. Besides, they also have a strong distribution network that makes them have the lion's share.

Other players are focusing on launching cheaper antithrombin products in order to be in the competition. They are also investing huge sums for research and development activities in order to develop new products. Some other companies are entering into collaborations with other companies in order to stay in the competition. Other companies operating in the global antithrombin market are Scripps Laboratories Inc., Octapharma AG, CSL Limited, Grifols, Lee Biosolutions, Kedrion S.p.A., Shire Plc., and LFB USA.

Get Customization:
https://www.fortunebusinessinsights.com/enquiry/customization/antithrombin-market-100470

About Us

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges

For more information on this press release visit: http://www.sbwire.com/press-releases/antithrombin-market-to-exhibit-41-cagr-rising-prevalence-of-hereditary-antithrombin-deficiency-to-boost-market-forecast-till-2026-1233593.htm

Media Relations Contact

Fortune Business Insights
Sales Manager
Fortune Business Insights
Telephone: 1-424-253-0390
Email: Click to Email Fortune Business Insights
Web: https://www.fortunebusinessinsights.com/industry-reports/antithrombin-market-100470

Latest News
Top News